Latest Research And Development News

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Eden Innovations is investing in new R&D equipment to enhance its carbon nanotube concrete technology, targeting the booming AI data centre market with improved heat dissipation and electromagnetic shielding.

Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.

AI-Media Technologies has reported a robust first half of FY26, achieving an 80% increase in annual recurring revenue driven by its LEXI suite and unveiling a new Hardware as a Service model set to transform its business.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.